22nd Century to Participate in Cowen and Roth Capital Investor Conferences in November 2021
November 11 2021 - 8:20AM
22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural
biotechnology company focused on tobacco harm reduction, reduced
nicotine tobacco, and improving health and wellness through plant
science, today announced that the Company will participate in the
following virtual investor conferences during the month of November
2021:
- On Tuesday, November 16, 2021, the Company
will host investor meetings at the Inaugural Roth Capital
Partners AgTech Answers Virtual Event. Roth Capital events
are intended for prospective and existing Roth Capital clients. To
request a meeting, please contact your Roth Capital
representative.
- On Tuesday, November 30, 2021, at 11:00 a.m.
ET, the Company will participate on a panel titled “Creative
Cannabis Exposure” as part of the Cowen 4th Annual Cannabis
Conference. The panel will be moderated by Cowen analyst
Vivian Azer, who covers the beverages, tobacco, and cannabis
sectors. The panel will be available to prospective and existing
Cowen clients.
Institutional investors and those invited to attend these
virtual conference events may request one-on-one meetings with
representatives of the Company, where offered, through the
respective conference hosts or by contacting 22nd Century Group’s
investor relations team via investorrelations@xxiicentury.com.
About 22nd Century Group, Inc.22nd Century
Group, Inc. (Nasdaq: XXII) is a leading agricultural
biotechnology company focused on tobacco harm reduction, reduced
nicotine tobacco and improving health and wellness through plant
science. With dozens of patents allowing it to control nicotine
biosynthesis in the tobacco plant, the Company has developed
proprietary reduced nicotine content (RNC) tobacco plants and
cigarettes, which have become the cornerstone of the FDA’s
Comprehensive Plan to address the widespread death and disease
caused by smoking. In tobacco, hemp/cannabis, and hop plants, 22nd
Century uses modern plant breeding technologies, including genetic
engineering, gene-editing, and molecular breeding to deliver
solutions for the life science and consumer products industries by
creating new, proprietary plants with optimized alkaloid and
flavonoid profiles as well as improved yields and valuable
agronomic traits.
Learn more at xxiicentury.com, on
Twitter @_xxiicentury, and on LinkedIn.
Cautionary Note Regarding
Forward-Looking StatementsExcept for historical
information, all of the statements, expectations, and assumptions
contained in this press release are forward-looking statements.
Forward-looking statements typically contain terms such as
“anticipate,” “believe,” “consider,” “continue,” “could,”
“estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,”
“intend,” “likely,” “may,” “plan,” “potential,” “predict,”
“preliminary,” “probable,” “project,” “promising,” “seek,”
“should,” “will,” “would,” and similar expressions. Actual results
might differ materially from those explicit or implicit in
forward-looking statements. Important factors that could cause
actual results to differ materially are set forth in “Risk Factors”
in the Company’s Annual Report on Form 10-K filed on March 11,
2021. All information provided in this release is as of the date
hereof, and the Company assumes no obligation to and does not
intend to update these forward-looking statements, except as
required by law.
Investor Relations & Media
Contact:Mei KuoDirector, Communications & Investor
Relations22nd Century Group, Inc.(716)
300-1221mkuo@xxiicentury.com
22nd Century (NASDAQ:XXII)
Historical Stock Chart
From Apr 2024 to May 2024
22nd Century (NASDAQ:XXII)
Historical Stock Chart
From May 2023 to May 2024